Tags

Type your tag names separated by a space and hit enter

Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.
Proc Nutr Soc 2007; 66(3):307-15PN

Abstract

Human subjects and their enteric microbiota have evolved together to reach a state of mutual tolerance. Mounting evidence from both animal models and human studies suggests that inflammatory bowel disease (IBD) represents a malfunction of this relationship. The enteric microecology therefore represents an attractive therapeutic target with few side effects. Probiotics and prebiotics have been investigated in clinical trials as treatments for IBD, with conflicting results. The evidence for the use of probiotics in the management of pouchitis is persuasive and several studies indicate their effectiveness in ulcerative colitis. Trials of probiotics and prebiotics in Crohn's disease are less convincing. However, methodologies vary widely and a range of probiotic, prebiotic and combination (synbiotic) treatments have been tested in a variety of patient groups with an assortment of end points. Conclusions about any one treatment in a specific patient group can therefore only be drawn on evidence from relatively small numbers of patients. The present article reviews the role of the intestinal microbiota in the pathogenesis of IBD and addresses the clinical evidence for the therapeutic manipulation of bowel microbiota using probiotics, prebiotics and synbiotics in IBD.

Authors+Show Affiliations

Nutritional Sciences Division, King's College London, London SE1 9NH, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17637082

Citation

Hedin, Charlotte, et al. "Evidence for the Use of Probiotics and Prebiotics in Inflammatory Bowel Disease: a Review of Clinical Trials." The Proceedings of the Nutrition Society, vol. 66, no. 3, 2007, pp. 307-15.
Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc. 2007;66(3):307-15.
Hedin, C., Whelan, K., & Lindsay, J. O. (2007). Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. The Proceedings of the Nutrition Society, 66(3), pp. 307-15.
Hedin C, Whelan K, Lindsay JO. Evidence for the Use of Probiotics and Prebiotics in Inflammatory Bowel Disease: a Review of Clinical Trials. Proc Nutr Soc. 2007;66(3):307-15. PubMed PMID: 17637082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. AU - Hedin,Charlotte, AU - Whelan,Kevin, AU - Lindsay,James O, PY - 2007/7/20/pubmed PY - 2007/10/13/medline PY - 2007/7/20/entrez SP - 307 EP - 15 JF - The Proceedings of the Nutrition Society JO - Proc Nutr Soc VL - 66 IS - 3 N2 - Human subjects and their enteric microbiota have evolved together to reach a state of mutual tolerance. Mounting evidence from both animal models and human studies suggests that inflammatory bowel disease (IBD) represents a malfunction of this relationship. The enteric microecology therefore represents an attractive therapeutic target with few side effects. Probiotics and prebiotics have been investigated in clinical trials as treatments for IBD, with conflicting results. The evidence for the use of probiotics in the management of pouchitis is persuasive and several studies indicate their effectiveness in ulcerative colitis. Trials of probiotics and prebiotics in Crohn's disease are less convincing. However, methodologies vary widely and a range of probiotic, prebiotic and combination (synbiotic) treatments have been tested in a variety of patient groups with an assortment of end points. Conclusions about any one treatment in a specific patient group can therefore only be drawn on evidence from relatively small numbers of patients. The present article reviews the role of the intestinal microbiota in the pathogenesis of IBD and addresses the clinical evidence for the therapeutic manipulation of bowel microbiota using probiotics, prebiotics and synbiotics in IBD. SN - 0029-6651 UR - https://www.unboundmedicine.com/medline/citation/17637082/Evidence_for_the_use_of_probiotics_and_prebiotics_in_inflammatory_bowel_disease:_a_review_of_clinical_trials_ L2 - https://www.cambridge.org/core/product/identifier/S0029665107005563/type/journal_article DB - PRIME DP - Unbound Medicine ER -